VISION & MISSION

IPMG seeks to be the trusted partner to the government of Indonesia and other stakeholders and to play an important role in improving the healthcare system through the core strengths of its members; i.e., medical innovation and manufacturing of products that meet international standards of pharmaceutical quality and safety.

Read More

COMMITMENT

As an organization, IPMG is committed to working with all healthcare sector stakeholders and to fully support government programs and regulations. IPMG and its members assiduously strive to ensure Indonesians have access to quality healthcare products.

Read More

ROLE

IPMG communicates the commitment and contribution of R&D-based pharmaceutical manufacturers in broadening access to innovative medicines, vaccines and biologics as well as in advocating and providing recommendations for the advancement of an effective and integrated healthcare system in Indonesia

Read More

Today, cutting-edge medical science is transforming patients’ lives. Discover how scientists and researchers are advancing science.

Read More

Pharmaceutical products that are pirated, counterfeited, or unregistered can be easily found in the Indonesian market, and pose serious health

Read More

Pharmaceutical companies rely on government-granted patents to protect their huge investments in researching and developing new medicines

Read More

IPMG News

Image

Socialization IPMG Code of Ethics 2021 Revision – Ethics and Compliance Task Force

Kudos to the #IPMG Ethics and Compliance task force for their hard work. This new revised National Code is setting the bar higher and seeks to embody a deeper and broader appreciation of business integrity. 

Image

IPMG Chairman, Ait-Allah Mejri sharing his insights:

IPMG Chairman, Ait-Allah Mejri sharing his insights:

Image

Pfizer fellowship to help elevate RI biotech sector

The COVID-19 pandemic is a wake-up call for the world to understand the centrality of the biotech sector. As countries struggle to contain the pandemic, governments and ordinary people alike have pinned their hopes on the biotech sector to discover effective treatments. This difficult time shows that countries with well-developed biotech sectors strive relatively better in facing the pandemic.

Image

Five Steps to Advance COVID-19 Vaccine Equity Step #3

Five Steps to Advance COVID-19 Vaccine Equity Step #3

IPMG Press Release

Image

Five Steps to Advance COVID-19 Vaccine Equity Step #3

Five Steps to Advance COVID-19 Vaccine Equity Step #3

Regulation

Image

Central LPPOM MUI Takes over Judicial Review against Halal Law

The Indonesian Ulema Council’s Assessment Institute for Foods, Drugs and Cosmetics (LPPOM MUI) in 31 provinces filed a judicial review against Halal Product Guarantee Law to the Constitutional Court. However, the central LPPOM MUI will take over the judicial review by prioritizing a dialogue, but remains accommodating aspirations from LPPOM MUI in the regions. LPPOM MUI Director Lukmanul Hakim said that there's possibly an information on halal certification that raises concerns of the LPPOM MUI in the regions.

Image

Hak Paten Jadi Tameng Keaslian Obat

Meskipun industri farmasi menggunakan paten obat untuk memastikan keeksklusifan pasar, namun hak paten biasanya hanya berlaku selama 20 tahun. Sepuluh tahun proses penelitian dan pengembangan obat, membuat industri farmasi terdorong untuk memperpanjang hak paten obat mereka agar riset dan keaslian akan suatu obat bisa dijaga.

Image

Advokasi Mengenai Regulasi Jaminan Produk Halal

Undang - Undang Nomor 33 tentang Jaminan Produk Halal (UU JPH) dibuat untuk melindungi masyarakat. Indonesia sebagai negara dengan mayoritas muslim tentu membutuhkan label halal pada suatu rpoduk, baik makanan maupun obat-obatan.

Image

Dugaan Suap Perusahan Farmasi-Dokter, Pengamat Sebut KPK Terlalu Naif

Jakarta - Praktisi hukum dari UIN Syarif Hidayatullah Andi Syafrani menilai KPK terlalu naif ketika membiarkan praktik kerja sama saling menguntungkan antara perusahaan farmasi dan institusi kedokteran.

Our Member

  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients
  • Clients